Longevity Medications and Supplements

 

The Potential of Rapamycin, Metformin, and Other Supplements in Longevity Medicine: Emerging Research and Clinical Implications

Rapamycin and metformin are two pharmacological agents that have garnered significant attention in longevity medicine due to their ability to modulate key biological pathways associated with aging and chronic disease. Rapamycin, a macrolide compound initially discovered as an antifungal agent, has been found to have immunosuppressive and anti-proliferative properties, leading to its approval for preventing organ transplant rejection. Its potential role in longevity medicine arises from its ability to inhibit the mechanistic target of rapamycin (mTOR) pathway, a central regulator of cellular growth, metabolism, and autophagy. (Li et al., 2014) Rapamycin selectively inhibits mTORC1, reducing cellular growth signals and promoting autophagy, clearing damaged organelles and proteins. (Li et al., 2014) In animal studies, rapamycin has consistently extended lifespan across multiple species, including yeast, worms, flies, and mice. (Li et al., 2014) It improves metabolic health, reduces inflammation, and protects against age-related diseases such as cancer, neurodegeneration, and cardiovascular disorders. (Li et al., 2014) However, concerns about immunosuppression and side effects, such as hyperlipidemia and insulin resistance, have spurred interest in optimizing dosing regimens, including intermittent use to balance benefits and risks. (Lamming et al., 2012)

Metformin, a widely used drug for type 2 diabetes, has emerged as another promising candidate for longevity medicine. It works primarily by activating AMP-activated protein kinase, a cellular energy sensor that enhances insulin sensitivity, promotes mitochondrial health, and indirectly inhibits mTOR signaling. (Soukas et al., 2019) Recent studies have indicated that eliminating damaged mitochondria via mitophagy may be one of the mechanisms responsible for the beneficial effects of rapamycin. (Chen et al., 2020) The antidiabetic effects of metformin and its exhibition of anti-aging properties in model organisms have garnered tremendous interest in its potential use as an anti-aging therapy. (Soukas et al., 2019) However, uncertainties exist in metformin's mechanisms and side effects that may prevent its widespread use in aging in otherwise healthy individuals. (Soukas et al., 2019)

Rapamycin and metformin have shown promising results in their potential to modulate key biological pathways associated with aging and chronic disease. Further research is needed to optimize their use and address the concerns regarding side effects and long-term safety.

Rapamycin and metformin have distinct mechanisms of action, but both target cellular pathways implicated in the aging process. Rapamycin inhibits the mTOR pathway, reducing cellular growth signals and promoting autophagy, while metformin activates AMPK, enhancing insulin sensitivity and inhibiting mTOR. (Li et al., 2014)(Soukas et al., 2019) Animal studies have consistently shown that rapamycin can extend lifespan across multiple species, and it has been found to improve metabolic health, reduce inflammation, and protect against age-related diseases. (Li et al., 2014) Metformin, on the other hand, has also exhibited anti-aging properties in model organisms, potentially through its ability to promote mitochondrial health and mitophagy. (Haes et al., 2014) (Chen et al., 2020)

While these pharmacological agents hold promise in longevity medicine, concerns and uncertainties must be addressed. Rapamycin's immunosuppressive effects and potential side effects, such as hyperlipidemia and insulin resistance, have led to the exploration of optimized dosing regimens, including intermittent use. (Lamming et al., 2012) Similarly, the widespread use of metformin as an anti-aging therapy in otherwise healthy individuals is limited by the incomplete understanding of its mechanisms of action and potential side effects. (Soukas et al., 2019)

Further research is necessary to elucidate the precise mechanisms by which rapamycin and metformin exert their anti-aging effects and develop strategies to mitigate their potential drawbacks. By continuing to investigate these pharmacological agents, researchers may pave the way for developing more effective and safer interventions to promote healthy aging and delay the onset of age-related diseases.

One key area of interest in studying rapamycin and metformin is their potential to modulate mitochondrial function and dynamics. Recent studies have indicated that rapamycin's beneficial effects may be mediated, at least in part, by its ability to enhance mitophagy and the selective degradation of damaged mitochondria. (Chen et al., 2020) Mitochondrial dysfunction is a hallmark of aging and a contributing factor to the development of various age-related diseases. Rapamycin may help maintain mitochondrial homeostasis and contribute to its anti-aging effects by promoting the clearance of dysfunctional mitochondria.

Similarly, metformin has been shown to activate AMPK, which can stimulate mitochondrial biogenesis and enhance mitochondrial function. (Haes et al., 2014) Through this mitohormetic pathway, metformin may elicit a beneficial response that counteracts the detrimental effects of aging on mitochondria.

As the understanding of the complex interplay between these pharmacological agents and mitochondrial biology continues to evolve, researchers may uncover novel strategies to harness the power of these drugs to promote healthy aging and mitigate the burden of age-related diseases.

In addition to well-studied interventions like rapamycin and metformin, other supplements are being investigated for their potential longevity benefits. One such compound is resveratrol, a polyphenol found in red wine that activates sirtuins, particularly SIRT1, which are involved in DNA repair, metabolic regulation, and mitochondrial function (Liu, 2022). Though promising in preclinical studies, human trials have yielded mixed results, partly due to poor bioavailability (Alarcón‐de‐la‐Lastra & Villegas, 2005).

Another focus of longevity research is on nicotinamide riboside and nicotinamide mononucleotide, which aim to replenish declining NAD+ levels observed with aging (Marsman et al., 2018). NAD+ is essential for mitochondrial function, DNA repair, and cellular energy metabolism, and early human studies suggest that supplementation with these NAD+ precursors may improve metabolic health and reduce markers of inflammation (Marsman et al., 2018).

Quercetin, a flavonoid with anti-inflammatory and antioxidant properties, is also being studied for its potential to enhance cellular resilience and combat senescence. Combined with the chemotherapeutic agent dasatinib, quercetin acts as a senolytic, selectively clearing senescent cells that contribute to aging and chronic inflammation (Singh et al., 2022).

Spermidine, a naturally occurring polyamine found in foods like wheat germ, promotes autophagy and has shown promise in preclinical models for extending lifespan and improving cardiovascular health (Johmura et al., 2021). Early human studies suggest it may also improve memory and reduce inflammation (Yang et al., 2020).

Other notable supplements with potential longevity benefits include omega-3 fatty acids, which support cardiovascular and brain health through anti-inflammatory mechanisms, and curcumin, the active component of turmeric, known for its ability to modulate inflammation and oxidative stress. Coenzyme Q10 and its reduced form, ubiquinol, are key components of the mitochondrial electron transport chain and have been shown to improve mitochondrial function, particularly in conditions of age-related decline (Mayor, 2023).

The emerging research on these and other longevity-promoting supplements highlights the complex and multifaceted nature of the aging process. As we unravel the underlying mechanisms, these compounds may offer promising strategies for maintaining health and delaying the onset of age-associated diseases.

While the supplements discussed have shown potential in preclinical and early human studies, it is important to note that the field of longevity research is still nascent, and more robust clinical trials are needed to establish the safety and efficacy of these interventions.

Pursuing longevity through dietary supplements and natural compounds is a rapidly evolving field of research. Compounds like resveratrol, NAD+ precursors, quercetin, spermidine, and others have demonstrated promising results in preclinical studies and early human trials, suggesting they may play a role in extending healthy lifespan and delaying age-related diseases.

As the global population ages, this research has significant implications for public health and the potential to improve the quality of life for older adults. However, more comprehensive clinical studies are needed to fully understand these interventions' long-term safety and efficacy.

While these supplements show promise, it is crucial to approach them with cautious optimism. A balanced, evidence-based approach, combined with ongoing research, will be essential in determining the true potential of these longevity-promoting compounds.

The future of longevity research lies in the continued exploration of these and other natural compounds and the development of novel interventions that target the underlying hallmarks of aging.

References

  1. Chen, G., Kroemer, G., & Kepp, O. (2020). Mitophagy: An Emerging Role in Aging and Age-Associated Diseases [Review of Mitophagy: An Emerging Role in Aging and Age-Associated Diseases]. Frontiers in Cell and Developmental Biology, 8. Frontiers Media. https://doi.org/10.3389/fcell.2020.00200

  2. Haes, W. D., Frooninckx, L., Assche, R. V., Smolders, A., Depuydt, G., Billen, J., Braeckman, B. P., Schoofs, L., & Temmerman, L. (2014). Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. In W. D. Haes, L. Frooninckx, R. V. Assche, A. Smolders, G. Depuydt, J. Billen, B. P. Braeckman, L. Schoofs, & L. Temmerman, Proceedings of the National Academy of Sciences (Vol. 111, Issue 24). National Academy of Sciences. https://doi.org/10.1073/pnas.1321776111

  3. Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., Guertin, D. A., Sabatini, D. M., & Baur, J. A. (2012). Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity. In D. W. Lamming, L. Ye, P. Katajisto, M. D. Goncalves, M. Saitoh, D. M. Stevens, J. G. Davis, A. B. Salmon, A. Richardson, R. S. Ahima, D. A. Guertin, D. M. Sabatini, & J. A. Baur, Science (Vol. 335, Issue 6076, p. 1638). American Association for the Advancement of Science. https://doi.org/10.1126/science.1215135

  4. Li, J., Kim, S. G., & Blenis, J. (2014). Rapamycin: One Drug, Many Effects [Review of Rapamycin: One Drug, Many Effects]. Cell Metabolism, 19(3), 373. Cell Press. https://doi.org/10.1016/j.cmet.2014.01.001

  5. Soukas, A. A., Hao, H., & Wu, L. (2019). Metformin as Anti-Aging Therapy: Is It for Everyone? [Review of Metformin as Anti-Aging Therapy: Is It for Everyone?]. Trends in Endocrinology and Metabolism, 30(10), 745. Elsevier BV. https://doi.org/10.1016/j.tem.2019.07.015

  6. Alarcón‐de‐la‐Lastra, C., & Villegas, I. (2005). Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications [Review of Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications]. Molecular Nutrition & Food Research, 49(5), 405. Wiley. https://doi.org/10.1002/mnfr.200500022

  7. Johmura, Y., Yamanaka, T., Omori, S., Wang, T.-W., Sugiura, Y., Matsumoto, M., Suzuki, N., Kumamoto, S., Yamaguchi, K., Hatakeyama, S., Takami, T., Yamaguchi, R., Shimizu, E., Ikeda, K., Okahashi, N., Mikawa, R., Suematsu, M., Arita, M., Sugimoto, M., … Nakanishi, M. (2021). Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders. In Y. Johmura, T. Yamanaka, S. Omori, T.-W. Wang, Y. Sugiura, M. Matsumoto, N. Suzuki, S. Kumamoto, K. Yamaguchi, S. Hatakeyama, T. Takami, R. Yamaguchi, E. Shimizu, K. Ikeda, N. Okahashi, R. Mikawa, M. Suematsu, M. Arita, M. Sugimoto, … M. Nakanishi, Science (Vol. 371, Issue 6526, p. 265). American Association for the Advancement of Science. https://doi.org/10.1126/science.abb5916

  8. Liu, J. (2022). Antiaging agents: safe interventions to slow aging and healthy life span extension [Review of Antiaging agents: safe interventions to slow aging and healthy life span extension]. Natural Products and Bioprospecting, 12(1). Springer Science+Business Media. https://doi.org/10.1007/s13659-022-00339-y

  9. Marsman, D. S., Belsky, D. W., Gregori, D., Johnson, M. A., Dog, T. L., Meydani, S. N., Pigat, S., Sadana, R., Shao, A., & Griffiths, J. C. (2018). Healthy ageing: the natural consequences of good nutrition—a conference report. In D. S. Marsman, D. W. Belsky, D. Gregori, M. A. Johnson, T. L. Dog, S. N. Meydani, S. Pigat, R. Sadana, A. Shao, & J. C. Griffiths, European Journal of Nutrition (Vol. 57, p. 15). Springer Science+Business Media. https://doi.org/10.1007/s00394-018-1723-0

  10. Mayor, E. (2023). Neurotrophic effects of intermittent fasting, calorie restriction and exercise: a review and annotated bibliography [Review of Neurotrophic effects of intermittent fasting, calorie restriction and exercise: a review and annotated bibliography]. Frontiers in Aging, 4. Frontiers Media. https://doi.org/10.3389/fragi.2023.1161814

  11. Singh, P., Kapahi, P., & Deursen, J. M. van. (2022, December 8). Immune checkpoint inhibitors as senolytic agents. In P. Singh, P. Kapahi, & J. M. van Deursen, Cell Research (Vol. 33, Issue 3, p. 197). Springer Nature. https://doi.org/10.1038/s41422-022-00761-4

  12. Yang, X., Zhang, M., Dai, Y.-H., Sun, Y., Aman, Y., Xu, Y., Yu, P., Zheng, Y., Yang, J., & Zhu, X. (2020). Spermidine inhibits neurodegeneration and delays aging via the PINK1-PDR1-dependent mitophagy pathway in C. elegans. In X. Yang, M. Zhang, Y.-H. Dai, Y. Sun, Y. Aman, Y. Xu, P. Yu, Y. Zheng, J. Yang, & X. Zhu, Aging (Vol. 12, Issue 17, p. 16852). Impact Journals LLC. https://doi.org/10.18632/aging.103578